ASX:RNO

Rhinomed (RNO) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
452,773 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
3.01%
Price Target
N/A

About Rhinomed

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

RNO Stock News Headlines

Insider Buyers Lose AU$435k As Rhinomed Sheds AU$1.4m
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
See More Headlines
Receive RNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhinomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2019
Today
5/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-10,910,000.00
Net Margins
-135.49%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8.05 million
Book Value
A($0.02) per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.88
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

RNO Stock Analysis - Frequently Asked Questions

How were Rhinomed's earnings last quarter?

Rhinomed Limited (ASX:RNO) issued its quarterly earnings results on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter. Rhinomed had a negative trailing twelve-month return on equity of 388.13% and a negative net margin of 135.49%.

This page (ASX:RNO) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners